Viridian Therapeutics is advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Our pipeline represents a patient-centric model of innovation, which leverages proven biology and technology to efficiently allocate research and development resources, while addressing strategic gaps related to access, delivery, quality of life, and efficacy in therapeutic areas of focus.
Viridian’s most advanced program, VRDN-001, is an anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody in development for thyroid eye disease (TED). This antibody was previously in development as AVE-1642, and was studied in more than 100 oncology patients; the pharmacokinetic, pharmacodynamic, safety, and tolerability data from that program inform our development plans for VRDN-001.
In 2020, the Company obtained exclusive worldwide rights from ImmunoGen, Inc. to develop, manufacture and commercialize VRDN-001 for all non-oncology indications that do not use radiopharmaceuticals, including the treatment of TED.
Learn more about AVE-1642’s history in oncology:
- Moreau, P et al. “Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma.” Leukemia vol. 25,5 (2011): 872-4. doi:10.1038/leu.2011.4
- Soria, Jean Charles et al. “A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours.” European journal of cancer (Oxford, England : 1990) vol. 49,8 (2013): 1799-807. doi:10.1016/j.ejca.2013.01.003
VRDN-002 is the Company’s second-generation product candidate, incorporating half-life extension technology, and is intended for subcutaneous administration.
TED is a debilitating auto-immune disease that causes inflammation and fibrosis of the orbital tissues surrounding the eye. This leads to proptosis, or bulging of the eyes, redness and swelling, diplopia (double vision), pain, and potential blindness. As the disease progresses, patients often have difficulty reading, driving and performing routine activities of daily living, leading to a high physical and mental burden and significantly impacting quality of life. Historically, these patients have had poor treatment options limited to orbital surgeries, radiation, and steroids. Currently there is one Food and Drug Administration (FDA)-approved treatment for TED, an intravenously administered monoclonal antibody that targets the insulin-like growth factor-1 receptor (IGF-1R). Our vision is to make such therapy more complete, more convenient, and more cost effective for TED patients.
Learn more about Viridian and our programs in our corporate presentation.